inclusion criteria: 1. confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation. 2. self-reported symptoms of sars-cov-2 infection including any of the following: fever ≥37.5°c, cough, dyspnea, chest tightness, malaise, sore throat, myalgias, or coryza 3. time from a positive test result to day 1 of treatment within 4 days 4. time from patient reported first symptoms to day 1 of treatment within 12 days 5. adults, age 18 and over, with any risk factor for severe disease 6. resident of alberta or if not a resident of alberta able to provide complete follow-up data 7. agrees to use adequate contraception for the duration of the study 8. informed consent

inclusion criteria: 1. confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation. 2. self-reported symptoms of sars-cov-2 infection including any of the following: fever ≥37.5°c, cough, dyspnea, chest tightness, malaise, sore throat, myalgias, or coryza 3. time from a positive test result to day 1 of treatment within 4 days 4. time from patient reported first symptoms to day 1 of treatment within 12 days 5. adults, age 18 and over, with any risk factor for severe disease 6. resident of alberta or if not a resident of alberta able to provide complete follow-up data 7. agrees to use adequate contraception for the duration of the study 8. informed consent

inclusion criteria: confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation. self-reported symptoms of sars-cov-2 infection including any of the following: fever ≥37.5°c, cough, dyspnea, chest tightness, malaise, sore throat, myalgias, or coryza time from a positive test result to day 1 of treatment within 4 days time from patient reported first symptoms to day 1 of treatment within 12 days adults, age 18 and over, with any risk factor for severe disease resident of alberta or if not a resident of alberta able to provide complete follow-up data agrees to use adequate contraception for the duration of the study informed consent

inclusion criteria: confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation. self-reported symptoms of sars-cov-2 infection including any of the following: fever ≥37.5°c, cough, dyspnea, chest tightness, malaise, sore throat, myalgias, or coryza time from a positive test result to day 1 of treatment within 4 days time from patient reported first symptoms to day 1 of treatment within 12 days adults, age 18 and over, with any risk factor for severe disease resident of alberta or if not a resident of alberta able to provide complete follow-up data agrees to use adequate contraception for the duration of the study informed consent

inclusion criteria: 1. confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation. 2. self-reported symptoms of sars-cov-2 infection including any of the following: fever ≥37.5°c, cough, dyspnea, chest tightness, malaise, sore throat, myalgias, or coryza 3. time from a positive test result to day 1 of treatment within 4 days 4. time from patient reported first symptoms to day 1 of treatment within 12 days 5. adults, age 18 and over, with any risk factor for severe disease 6. resident of alberta or if not a resident of alberta able to provide complete follow-up data 7. agrees to use adequate contraception for the duration of the study 8. informed consent

inclusion criteria: 1. confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation. 2. self-reported symptoms of sars-cov-2 infection including any of the following: fever ≥37.5°c, cough, dyspnea, chest tightness, malaise, sore throat, myalgias, or coryza 3. time from a positive test result to day 1 of treatment within 4 days 4. time from patient reported first symptoms to day 1 of treatment within 12 days 5. adults, age 18 and over, with any risk factor for severe disease 6. resident of alberta or if not a resident of alberta able to provide complete follow-up data 7. agrees to use adequate contraception for the duration of the study 8. informed consent